PROCEPT BioRobotics Corporation cash flow to debt ratio of -94.90% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

PROCEPT BioRobotics Corporation's free cash flow has increased -43.70% from $-103.62M last year to $-58.34M, signaling increasing performance

PROCEPT BioRobotics Corporation's debt to equity ratio is 0.15, which means that the company's assets are healthy financed, signaling financial stability. READ MORE: A ratio under 0.60 means the company finances its assets with own equity, signaling financial stability and good management.

PROCEPT BioRobotics Corporation's debt has decreased relative to shareholder equity from 0.20 last year to 0.15 today, signaling strengthened financials

PROCEPT BioRobotics Corporation has negative EBITDA, making leverage ratio unreliable

PROCEPT BioRobotics Corporation earns at least as much interest as it pays. Interest obligations are fully covered.

PROCEPT BioRobotics Corporation's profit margin has increased (-21.85%) in the last year from -40.72% to -31.82%, signaling increasing performance

PROCEPT BioRobotics Corporation's short-term assets of $450.38M exceed its short-term liabilities of $65.80M

PROCEPT BioRobotics Corporation's return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

PROCEPT BioRobotics Corporation's return on equity of -27.70%, is lower than 15.00%, indicating bad performance

PROCEPT BioRobotics Corporation's operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

PROCEPT BioRobotics Corporation had positive net income in only 0.00 out of 5 years, indicating unstable earnings

PROCEPT BioRobotics Corporation has negative free cash flow, indicating the company is burning cash rather than generating it

PROCEPT BioRobotics Corporation has negative free cash flow, indicating cash burn

PROCEPT BioRobotics Corporation's yearly earnings has decreased 4.55% since last year from $-91.41M to $-95.57M, signaling decreasing performance

PROCEPT BioRobotics Corporation's yearly revenue has increased 37.22% since last year from $224.50M to $308.05M, signaling increasing performance

ROIC -25.75% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

PROCEPT BioRobotics Corporation's 3-year revenue CAGR of 60.14% is positive, indicating growing revenue over the past 3 years

PROCEPT BioRobotics Corporation had revenue growth in 5.00 out of 5 years, indicating consistent revenue performance

PROCEPT BioRobotics Corporation had positive ROE in only 0.00 out of 5 years, indicating inconsistent returns on equity

PROCEPT BioRobotics Corporation has insufficient data to evaluate this check.

PROCEPT BioRobotics Corporation has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

PROCEPT BioRobotics Corporation is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

PROCEPT BioRobotics Corporation has negative or missing EBITDA, making EV/EBITDA ratio unreliable

PROCEPT BioRobotics Corporation is overvalued relative to its fair value price of -86.05 based on Earnings Fair Value model

PROCEPT BioRobotics Corporation has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

PROCEPT BioRobotics Corporation has a price-to-book ratio of 3.14x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

PROCEPT BioRobotics Corporation has a price-to-sales ratio of 3.39x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue